Exact Sciences Corporation (EXAS) Bundle
Understanding Exact Sciences Corporation (EXAS) Revenue Streams
Understanding Exact Sciences Corporation’s Revenue Streams
Exact Sciences Corporation generates revenue primarily through its laboratory services, focusing on cancer screening and diagnostic tests. The company’s revenue can be categorized into key segments: Screening and Precision Oncology.
Breakdown of Primary Revenue Sources
| Revenue Source | Q3 2024 Revenue (in millions) | Q3 2023 Revenue (in millions) | Change (in millions) |
|---|---|---|---|
| Screening | 544.9 | 472.0 | 72.9 |
| Precision Oncology | 163.8 | 156.3 | 7.4 |
| Total Revenue | 708.7 | 628.3 | 80.3 |
For the nine months ended September 30, 2024, the revenue breakdown is as follows:
| Revenue Source | 9M 2024 Revenue (in millions) | 9M 2023 Revenue (in millions) | Change (in millions) |
|---|---|---|---|
| Screening | 1,551.3 | 1,378.0 | 173.3 |
| Precision Oncology | 494.1 | 468.9 | 25.2 |
| COVID-19 Testing | — | 6.0 | (6.0) |
| Total Revenue | 2,045.4 | 1,852.9 | 192.5 |
Year-over-Year Revenue Growth Rate
Exact Sciences experienced a 13% year-over-year revenue growth in Q3 2024 compared to Q3 2023. This growth is attributed to increased test volumes across its Screening and Precision Oncology segments.
Contribution of Different Business Segments to Overall Revenue
During Q3 2024, the Screening segment contributed 77% of the total revenue, while the Precision Oncology segment accounted for 23%. This trend showcases the strength of the Screening services, particularly the Cologuard test, which continues to see expanding adoption.
Analysis of Significant Changes in Revenue Streams
The increase in revenue from the Screening segment was primarily due to a higher number of completed Cologuard tests driven by:
- Growth across various customer segments.
- More patients rescreening with Cologuard.
- Expansion of organized screening programs led by payers and health systems.
In Precision Oncology, the growth was mainly due to an increase in completed Oncotype DX breast cancer tests, particularly in international markets, including Japan, where reimbursement has been secured.
Moreover, the company has ceased its COVID-19 testing business, which contributed to a decline in that revenue stream, reflecting a strategic shift back to core cancer diagnostics.
Overall, Exact Sciences is positioned for continued growth in its core cancer screening and diagnostic services, as evidenced by the positive trends in both revenue segments.
A Deep Dive into Exact Sciences Corporation (EXAS) Profitability
A Deep Dive into Exact Sciences Corporation's Profitability
Gross Profit Margin: For the nine months ended September 30, 2024, the gross profit was approximately $1,489.4 million, resulting in a gross profit margin of 72.8%. This is an improvement from 72.4% in the same period of 2023.
Operating Profit Margin: The operating loss for the nine months ended September 30, 2024, was $164.3 million, resulting in an operating profit margin of (8.0%). In comparison, the operating loss for the same period in 2023 was $154.4 million, which translated to an operating profit margin of (8.3%).
Net Profit Margin: The net loss for the nine months ended September 30, 2024, was $164.3 million, yielding a net profit margin of (8.0%). This compares to a net loss of $154.4 million for the same period in 2023, which also resulted in a net profit margin of (8.3%).
Trends in Profitability Over Time
In examining the trends, the company has experienced fluctuations in profitability metrics. The gross profit margin has shown a slight increase from 72.4% in 2023 to 72.8% in 2024. However, the operating and net profit margins have remained negative, indicating ongoing challenges in achieving profitability despite revenue growth.
Comparison of Profitability Ratios with Industry Averages
The industry average gross profit margin for the healthcare sector is approximately 75%. The company's gross profit margin of 72.8% is slightly below this benchmark. In terms of operating and net profit margins, the industry averages are around 10% and 8%, respectively, indicating that the company is underperforming in these areas.
Analysis of Operational Efficiency
The total revenue for the nine months ended September 30, 2024, was approximately $2,045.4 million, reflecting a year-over-year increase of 10.4% from $1,852.9 million in 2023. Cost management has been a focal point, with total cost of sales increasing to $556.0 million in 2024 from $482.4 million in 2023.
| Metric | 2024 | 2023 | Change |
|---|---|---|---|
| Gross Profit Margin | 72.8% | 72.4% | +0.4% |
| Operating Profit Margin | (8.0%) | (8.3%) | +0.3% |
| Net Profit Margin | (8.0%) | (8.3%) | +0.3% |
| Total Revenue | $2,045.4M | $1,852.9M | +10.4% |
| Total Cost of Sales | $556.0M | $482.4M | +15.3% |
Cost management strategies have focused on optimizing operational efficiency, with total operating expenses for the nine months ending September 30, 2024, reaching $1,155.7 million, up from $1,007.3 million in 2023. As a result, the company has been able to leverage revenue growth while attempting to reduce the rate of increase in operating expenses.
Overall, while the company has made strides in gross profit margin improvement, the operating and net margins indicate that profitability remains a significant challenge as the company continues to invest in growth and operational efficiencies.
Debt vs. Equity: How Exact Sciences Corporation (EXAS) Finances Its Growth
Debt vs. Equity: How Exact Sciences Corporation Finances Its Growth
As of September 30, 2024, the company had total debt of approximately $2.57 billion, comprised of $2.57 billion in convertible notes and $249 million in current liabilities related to these notes. The total liabilities amounted to $3.54 billion.
Debt Levels
The company's long-term debt consists entirely of convertible notes, which include:
- 2030 Notes: $73 million at 2.0% interest, maturing on March 1, 2030.
- 2031 Notes: $620.7 million at 1.75% interest, maturing on April 15, 2031.
In addition to this, the company has access to a revolving line-of-credit of $150 million, which had not been drawn upon as of the latest reporting.
Debt-to-Equity Ratio
The debt-to-equity ratio stands at approximately 0.77 based on total liabilities of $3.54 billion and stockholders’ equity of $4.6 billion. This ratio is below the industry average of around 1.0, suggesting a more conservative approach to leveraging.
Recent Debt Issuances and Credit Ratings
In April 2024, the company issued $620.7 million in 1.75% convertible notes due in 2031, exchanging $359.7 million of existing 2028 notes. The net proceeds from this issuance were approximately $259.8 million. The company's credit rating remains stable, reflecting its ongoing operational improvements and revenue growth.
Balance Between Debt Financing and Equity Funding
The company has historically financed its operations through public offerings of common stock and convertible debt. As of September 30, 2024, total equity stood at $4.6 billion, with common stock totaling $1.85 billion and additional paid-in capital of $6.84 billion. The balance between debt and equity funding is essential for maintaining liquidity while pursuing growth opportunities in the cancer diagnostics market.
| Debt Instrument | Amount ($ million) | Interest Rate (%) | Maturity Date |
|---|---|---|---|
| 2030 Notes | 73.0 | 2.0 | March 1, 2030 |
| 2031 Notes | 620.7 | 1.75 | April 15, 2031 |
| Revolving Line of Credit | 150.0 | N/A | November 2025 |
This structured approach to financing allows the company to leverage its growth potential while managing its debt levels effectively, positioning itself for future expansion in the competitive healthcare sector.
Assessing Exact Sciences Corporation (EXAS) Liquidity
Assessing Exact Sciences Corporation's Liquidity
Current Ratio: As of September 30, 2024, the current ratio is calculated as follows:
| Current Assets | Current Liabilities | Current Ratio |
|---|---|---|
| $1,533,117,000 | $723,662,000 | 2.12 |
Quick Ratio: The quick ratio, which excludes inventory from current assets, is as follows:
| Current Assets (excluding inventory) | Current Liabilities | Quick Ratio |
|---|---|---|
| $1,396,130,000 | $723,662,000 | 1.93 |
Working Capital Trends: For the nine months ended September 30, 2024, the working capital is:
| Working Capital | September 30, 2024 | December 31, 2023 |
|---|---|---|
| Working Capital | $809,455,000 | $679,668,000 |
Cash Flow Overview: The cash flow statement highlights the following for the nine months ended September 30, 2024:
| Cash Flow Type | 2024 (in millions) | 2023 (in millions) |
|---|---|---|
| Operating Activities | $163.5 | $86.6 |
| Investing Activities | ($400.3) | $116.4 |
| Financing Activities | $221.4 | $149.7 |
Potential Liquidity Concerns or Strengths: As of September 30, 2024, the company has:
- $588.8 million in cash and cash equivalents.
- $432.3 million in marketable securities.
- Access to a revolving line of credit of $150 million, with $145.6 million available after accounting for letters of credit.
- Total liabilities of $3.54 billion, resulting in a total debt to equity ratio of approximately 1.10.
Overall, the liquidity position reflects a strong ability to cover short-term obligations, supported by significant cash reserves and marketable securities.
Is Exact Sciences Corporation (EXAS) Overvalued or Undervalued?
Valuation Analysis
As of September 30, 2024, the company reported a price-to-earnings (P/E) ratio of -10.51, reflecting its current net loss of $164.3 million for the nine months ended September 30, 2024. The price-to-book (P/B) ratio stands at 1.33, calculated using a book value of $3.21 billion and total shares outstanding of 185.05 million. The enterprise value-to-EBITDA (EV/EBITDA) ratio is approximately -28.64, indicating the negative earnings before interest, taxes, depreciation, and amortization.
| Valuation Metric | Value |
|---|---|
| P/E Ratio | -10.51 |
| P/B Ratio | 1.33 |
| EV/EBITDA | -28.64 |
| Book Value | $3.21 billion |
| Total Shares Outstanding | 185.05 million |
Over the last 12 months, the stock price has fluctuated significantly. As of October 2023, it was trading at approximately $48.00, and by September 30, 2024, the price had decreased to about $36.00, representing a decline of 25%.
The company does not currently pay dividends, as it has consistently reported net losses and maintains an accumulated deficit of approximately $3.63 billion.
Analyst consensus on the stock's valuation shows a mix of opinions, with 40% rating it as a "buy," 50% as a "hold," and 10% as a "sell".
| Analyst Rating | Percentage |
|---|---|
| Buy | 40% |
| Hold | 50% |
| Sell | 10% |
In summary, the current valuation metrics and stock performance suggest that the company is facing challenges, leading to a cautious outlook from analysts and investors alike.
Key Risks Facing Exact Sciences Corporation (EXAS)
Key Risks Facing Exact Sciences Corporation
Industry Competition: The company operates in a highly competitive market for cancer screening and diagnostic tests. Competitors may introduce innovative products that could capture market share. For instance, in 2024, major competitors launched advanced screening tests, impacting the company’s revenue streams.
Regulatory Changes: Regulatory scrutiny is a significant risk. The company’s products are subject to strict FDA regulations. Any changes in regulatory policies could delay product approvals or increase compliance costs. The recent FDA approval for Cologuard PlusTM in October 2024 illustrates the ongoing regulatory landscape the company navigates.
Market Conditions: Economic downturns could lead to reduced healthcare spending, affecting the demand for testing services. The company reported a total revenue of $2,045.4 million for the nine months ended September 30, 2024, an increase from $1,852.9 million in the same period of 2023, reflecting resilience but also highlighting market volatility risks.
Operational Risks
Production and Supply Chain Disruptions: The company faces risks related to the manufacturing and supply of its testing kits. Any disruptions could impact the availability of tests. For instance, the company reported an increase in production costs to $196.1 million for the three months ended September 30, 2024, up from $168.5 million in 2023.
Intellectual Property Risks: The company relies on proprietary technology for its tests. Legal challenges or patent infringement claims from competitors could hinder operations. As of September 30, 2024, the company had an accumulated deficit of approximately $3.63 billion, reflecting ongoing investments in R&D and potential vulnerabilities in its intellectual property strategy.
Financial Risks
Liquidity and Capital Resources: The company has historically financed operations through public offerings and debt. As of September 30, 2024, the company reported approximately $588.8 million in unrestricted cash and cash equivalents and $432.3 million in marketable securities. However, ongoing operational costs may necessitate additional capital raises.
Debt Obligations: The company’s long-term debt obligations pose a risk. As of September 30, 2024, total liabilities were approximately $3.54 billion, including convertible notes of $2.57 billion. The interest expense for the nine months ended September 30, 2024, was $17.4 million, reflecting the financial burden of servicing this debt.
Strategic Risks
Market Penetration Risks: The company seeks to expand its market share, particularly in international markets. The success of these efforts is contingent on factors such as reimbursement rates and healthcare policies in different regions. In 2024, the company secured reimbursement for its Oncotype DX test in Japan, which could enhance its market presence.
Research and Development Risks: Significant investments in R&D are crucial for future growth. The company reported R&D expenses of $331.6 million for the nine months ended September 30, 2024. The risk lies in the potential failure of new products to gain market acceptance or meet regulatory standards.
| Risk Factor | Description | Financial Impact |
|---|---|---|
| Industry Competition | Emergence of new products from competitors. | Potential revenue loss. |
| Regulatory Changes | Changes in FDA regulations affecting product approvals. | Increased compliance costs. |
| Market Conditions | Economic downturns affecting healthcare spending. | Decrease in demand for testing services. |
| Production Disruptions | Supply chain issues impacting test availability. | Increased costs and potential revenue loss. |
| Debt Obligations | High levels of debt increasing interest expenses. | Financial strain on operations. |
Mitigation Strategies: The company aims to mitigate these risks by enhancing operational efficiencies, diversifying its product portfolio, and actively engaging with regulatory bodies to ensure compliance. As of September 30, 2024, the company has not drawn any funds under its $150 million revolving line of credit, providing additional flexibility for managing its financial health.
Future Growth Prospects for Exact Sciences Corporation (EXAS)
Future Growth Prospects for Exact Sciences Corporation
Analysis of Key Growth Drivers
The company is positioned for growth through several key drivers, including product innovations and market expansions. Notably, the recent FDA approval of Cologuard Plus, a next-generation colorectal cancer screening test, is expected to enhance market penetration and drive revenue growth.
Revenue Growth Projections and Earnings Estimates
For the three months ended September 30, 2024, the company's total revenue reached $708.7 million, reflecting a year-over-year increase of 13% from $628.3 million in 2023. For the nine months ended September 30, 2024, total revenue was $2.045 billion, up from $1.853 billion in the same period of 2023, representing a growth of 10.4%.
| Revenue Source | Q3 2024 (in millions) | Q3 2023 (in millions) | 9M 2024 (in millions) | 9M 2023 (in millions) |
|---|---|---|---|---|
| Screening | $544.9 | $472.0 | $1,551.3 | $1,378.0 |
| Precision Oncology | $163.8 | $156.3 | $494.1 | $468.9 |
| Total Revenue | $708.7 | $628.3 | $2,045.4 | $1,852.9 |
Strategic Initiatives and Partnerships
The company has secured reimbursement for its Oncotype DX tests in Japan, which could potentially lead to more than 100 patients benefiting daily from this test. This expansion into international markets is a significant strategic initiative aimed at increasing the adoption rates of its oncology tests.
Competitive Advantages
Exact Sciences maintains a competitive edge through its comprehensive portfolio of innovative diagnostic tests, including its flagship products, Cologuard and Oncotype DX. The company has delivered test results to 1.2 million patients in the past quarter, showcasing its operational capacity and market reach. The growth in completed tests is attributed to increased patient rescreening and organized screening programs.
Financial Performance Overview
As of September 30, 2024, the company reported an accumulated deficit of approximately $3.63 billion. However, cash provided by operating activities improved to $138.7 million for the three months ended September 30, 2024, an increase of $114.4 million compared to the same quarter of 2023.
| Financial Metrics | Q3 2024 | Q3 2023 |
|---|---|---|
| Cash and Cash Equivalents | $588.8 million | $605.4 million |
| Marketable Securities | $432.3 million | $172.3 million |
| Net Income (Loss) | $(38.2 million) | $0.8 million |
| Operating Expenses | $751.2 million | $693.5 million |
Exact Sciences Corporation (EXAS) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Updated on 16 Nov 2024
Resources:
- Exact Sciences Corporation (EXAS) Financial Statements – Access the full quarterly financial statements for Q3 2024 to get an in-depth view of Exact Sciences Corporation (EXAS)' financial performance, including balance sheets, income statements, and cash flow statements.
- SEC Filings – View Exact Sciences Corporation (EXAS)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.